SCAN Brain Discovery Parkinson’s Hope

SCAN Brain Network Discovery Offers Hope Parkinson’s Treatment

Why in the News ?

A recent study has identified a new brain network called SCAN (Somatic Cognitive Action Network) linked to Parkinson’s disease, offering potential for improved therapies like targeted transcranial magnetic stimulation (TMS), which showed reduced symptoms in early clinical trials.

SCAN Brain Discovery Parkinson's Hope

Discovery of SCAN and Its Role:

  • New brain network: Scientists identified SCAN (Somatic Cognitive Action Network) as a key player in Parkinson’s.
  • Higher-order network: SCAN integrates motor control with cognitive functions like planning and coordination.
  • Research method: Discovery enabled by Precision Functional Mapping (PFM), improving brain imaging accuracy.
  • Beyond motor cortex: Challenges earlier belief that only motor-effector regions control movement.
  • Three-dot pattern: SCAN regions appear as distinct zones between motor areas.
  • Connectivity findings: Shows abnormal over-connection with basal ganglia and thalamus in Parkinson’s patients.
  • Large dataset: Study analysed data from 863 patients, enhancing reliability.
  • Disease specificity: SCAN abnormalities not seen in ALS, suggesting specificity to Parkinson’s.
  • Network dysfunction: Indicates Parkinson’s is linked to disrupted brain network coordination, not just localized damage.
  • Biomarker potential: SCAN may act as a network-level biomarker for diagnosis and monitoring.

Implications for Treatment and Therapies

  • Limitations of current treatments:

○   Levodopa: Variable efficacy and causes side-effects with long-term use.

○   Deep Brain Stimulation (DBS): Effective but invasive and expensive.

  • Emerging therapy: Transcranial Magnetic Stimulation (TMS) offers a non-invasive alternative.
  • Clinical trial results:

○   18 patients tested

○   SCAN-targeted TMS showed reduced tremors, rigidity, and instability

  • Mechanism: Improvement linked to reduction in SCAN over-connectivity.
  • Precision medicine: Future therapies may use individualised brain mapping (PFM).
  • Accessibility advantage: SCAN located near the brain surface → easier to target non-invasively.
  • Consistency across therapies: Effective treatments correlate with normalisation of SCAN activity.
  • Potential shift: Moves treatment focus from symptom control to network correction.
  • Early-stage evidence: Requires further validation before clinical adoption.
  • Future outlook: Combination of non-invasive and minimally invasive therapies likely.

About Parkinson’s Disease and Brain Science Basics:

●  Parkinson’s disease: A neurodegenerative disorder affecting movement and coordination.

●  Global burden: Affects over 10 million people worldwide.

●  Key symptoms: Tremors, rigidity, slowness (bradykinesia), and postural instability.

●  Affected brain regions: Primarily involves basal ganglia and dopamine pathways.

●  Dopamine role: Neurotransmitter essential for smooth motor function.

●  Traditional model: Focus on motor cortex and individual body-part control areas.

●  New paradigm: Emphasis on brain networks (like SCAN) for integrated functioning.

●  Imaging techniques:

○   fMRI: Measures brain activity

○   Electrocorticography: Records electrical signals

●  Neuromodulation therapies: Include DBS and TMS to alter brain activity.

●      Research significance: Advances understanding of complex brain organisation and disease mechanisms.